Semaglutide pills vs injection: what's actually different?

How do the pill and the injection actually compare?

The clearest way to see the differences is side by side. Both products contain semaglutide and are made by Novo Nordisk; both are licensed in the UK for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure or high cholesterol. Beyond that, the two forms diverge in some meaningful ways.

Trial figures above are sourced from the STEP 1 trial published in the New England Journal of Medicine and the MHRA approval announcement of 11 June 2026. The 7.2mg injection figures come from data supporting the MHRA's approval of the single-dose 7.2mg Wegovy pen. Numbers reflect trial populations; individual results vary and no outcome can be guaranteed.

Does the pill work as well as the injection?

In clinical terms, the injection has the edge on headline weight-loss figures, particularly at the higher 7.2mg dose, which produced around 20.7% average weight loss over 72 weeks. The tablet's OASIS 4 trial reported approximately 13.6% average weight loss at 64 weeks, rising to around 16.6% among participants who stayed fully adherent throughout. That fully-adherent figure is worth noting because it shows the tablet is capable of meaningful results when taken consistently; the gap with the injection narrows considerably when patients follow the daily routine. If you are weighing up the two routes, our detailed comparison of semaglutide tablets vs injection sets out the clinical differences in plain terms. What the pill cannot replicate yet is the injection's longer track record, Wegovy has been used in clinical practice for several years and has a substantial real-world evidence base, whereas the tablet is new to the UK market as of summer 2026.

Side effects overlap considerably. Both forms produce a GI-led profile: nausea, diarrhoea, constipation and indigestion are the most commonly reported, and they tend to be most noticeable when starting treatment or moving up to a new dose. In OASIS 4, 74% of tablet users reported gastrointestinal effects versus 42% on placebo, and most were described as mild to moderate and transient. The NHS medicines page for semaglutide covers the full side-effect profile for both forms and is a useful plain-language reference. If you'd like to read more about how the tablet compares in practice, our page on semaglutide tablets goes into the detail of the pill specifically.

One meaningful practical difference: the tablet needs to be taken first thing in the morning on an empty stomach, with a small amount of plain water (up to about 120ml). You then wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medicines. That routine is non-negotiable, it directly affects how much semaglutide is absorbed. For some people that's no trouble at all; for others, the weekly injection is simply easier to fit around work shifts or an unpredictable morning schedule.

Who might lean towards the pill, and who towards the injection?

If you have a strong aversion to needles, or your lifestyle makes refrigerated storage difficult (regular travel, for instance, or a home without a reliable fridge) the tablet is worth discussing. No injections, no sharps to dispose of, and it sits at room temperature. For readers who find the thought of a weekly self-injection a genuine barrier, that honestly matters. Our page on semaglutide pill versus injection explores exactly this kind of decision in more depth, including what questions to raise with your prescriber.

If you've been on the injection before and are wondering whether to switch, or if you'd like to explore what the higher-dose 7.2mg injection might offer, the conversation looks different again. You can find a broader overview of both routes on our weight-loss treatment overview, and for a different angle on the same question our page on whether semaglutide is oral or injection is worth a read.

Eligibility also plays a role. The licensed BMI thresholds are the same for both forms, but the NICE-recommended NHS route for the injection (under NICE TA875) requires use within a specialist weight management service for a maximum of two years, conditions that don't currently apply to the tablet, which has no NICE appraisal yet and is available only as a private prescription. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance; a prescriber will confirm the details at consultation. Neither form is licensed for use during pregnancy, breastfeeding or while trying to conceive, and neither is licensed for anyone under 18.

The oral contraceptive interaction is specific to the injection form: women taking the pill by mouth should add a non-oral method of contraception for the first four weeks of semaglutide injection treatment and for four weeks after each dose increase. Current guidance does not record the same requirement for the semaglutide tablet, but always confirm contraception with your prescriber. A common question at this stage is whether Wegovy comes as pills or as an injection, and our dedicated page on that topic explains how both licensed forms now sit alongside each other in the UK. Our clinical team keeps across the latest guidance on exactly this kind of practical question.

Which form suits you is a clinical decision made with a prescriber who knows your full picture, not something a web page can resolve. If you're ready to have that conversation, you can start your free consultation with our team today. There's no commitment, no fee for the consultation itself, and a GPhC-registered prescriber will review your answers the same day.